Pre-Sutured Tendon

K253145 · Rti Surgical, Inc. · GAT · Oct 22, 2025 · General, Plastic Surgery

Device Facts

Record IDK253145
Device NamePre-Sutured Tendon
ApplicantRti Surgical, Inc.
Product CodeGAT · General, Plastic Surgery
Decision DateOct 22, 2025
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 878.5000
Device ClassClass 2
AttributesTherapeutic

Intended Use

The Pre-Sutured Tendon is intended for use as a construct in anterior cruciate ligament and posterior cruciate ligament reconstruction. The Pre-Sutured Tendon is for single patient use only.

Device Story

Pre-Sutured Tendon consists of donated human non-bone tendon pre-sutured with sterile UHMWPE nonabsorbable sutures; processed via BioCleanse Tissue Sterilization Process. Offered as single or quadruple strands. Used by surgeons in orthopedic procedures for ACL and PCL reconstruction. Device serves as structural construct for ligament replacement. Benefits include standardized, pre-prepared graft construct for surgical implantation.

Clinical Evidence

Bench testing only. Testing included ultimate load, cyclic displacement, suture pull-out, packaging validation, tissue sterilization/viral inactivation, shelf-life, biocompatibility, and bacterial endotoxin testing. Results demonstrate equivalence to the predicate device.

Technological Characteristics

Donated human non-bone tendon; UHMWPE nonabsorbable sutures. Processed via BioCleanse Tissue Sterilization Process. Single strand (180-300mm length, 8-12mm diameter) or quadruple strand (50-85mm length, 8-13mm diameter).

Indications for Use

Indicated for patients requiring anterior cruciate ligament (ACL) or posterior cruciate ligament (PCL) reconstruction.

Regulatory Classification

Identification

Nonabsorbable poly(ethylene terephthalate) surgical suture is a multifilament, nonabsorbable, sterile, flexible thread prepared from fibers of high molecular weight, long-chain, linear polyesters having recurrent aromatic rings as an integral component and is indicated for use in soft tissue approximation. The poly(ethylene terephthalate) surgical suture meets U.S.P. requirements as described in the U.S.P. Monograph for Nonabsorbable Surgical Sutures; it may be provided uncoated or coated; and it may be undyed or dyed with an appropriate FDA listed color additive. Also, the suture may be provided with or without a standard needle attached.

Special Controls

*Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0} FDA U.S. FOOD & DRUG ADMINISTRATION October 22, 2025 RTI Surgical, Inc. Ellen Rounds Senior Regulatory Affairs Specialist 11621 Research Circle Alachua, Florida 32615 Re: K253145 Trade/Device Name: Pre-Sutured Tendon Regulation Number: 21 CFR 878.5000 Regulation Name: Nonabsorbable Poly(Ethylene Terephthalate) Surgical Suture Regulatory Class: Class II Product Code: GAT Dated: September 25, 2025 Received: September 25, 2025 Dear Ellen Rounds: We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. U.S. Food & Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 www.fda.gov {1} K253145 - Ellen Rounds Page 2 Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device" (https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download). Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30, Design controls; 21 CFR 820.90, Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review, the QS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181). Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050. All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems. For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory- {2} K253145 - Ellen Rounds Page 3 assistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Thomas Mcnamara -S For: Christopher Ferreira, M.S. Assistant Director DHT6C: Division of Restorative, Repair, and Trauma Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health Enclosure {3} | Indications for Use | | | | --- | --- | --- | | Please type in the marketing application/submission number, if it is known. This textbox will be left blank for original applications/submissions. | K253145 | ? | | Please provide the device trade name(s). | | ? | | Pre-Sutured Tendon | | | | Please provide your Indications for Use below. | | ? | | The Pre-Sutured Tendon is intended for use as a construct in anterior cruciate ligament and posterior cruciate ligament reconstruction. The Pre-Sutured Tendon is for single patient use only. | | | | Please select the types of uses (select one or both, as applicable). | ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) | ? | {4} K253145 Page 1/2 rti surgical 510(k) Summary | Date Prepared: | October 22nd, 2025 | | | | --- | --- | --- | --- | | Submitter: | RTI Surgical, Inc. 11621 Research Circle Alachua, FL 32615 USA | | | | Contact Information: | Ellen Rounds Senior Regulatory Affairs Specialist Email: erounds@rtix.com | | | | Name of Device: | Pre-Sutured Tendon | | | | Common Name: | Pre-Sutured Tendon (PST) | | | | Classification Name: | Suture, Nonabsorbable, Synthetic, Polyethylene | | | | Regulation Number: | 21 CFR 878.5000 | | | | Regulatory Class: | Class II | | | | Product Code: | GAT | | | | Panel: | Orthopedic | | | | Legally Marketed Predicate Device(s): | K230036 - Pre-Sutured Tendon | | | | Device Description: | The Pre-Sutured Tendon is a donated human nonbone tendon pre-sutured with sterile Ultra-high-molecular-weight polyethylene (UHMWPE) nonabsorbable sutures. The tendon is processed via the BioCleanse® Tissue Sterilization Process (The BioCleanse Process). The Pre-Sutured Tendon device is offered as a single strand and as a quadruple (quad) strand. | | | | | Implant | Dimensions | | | | | Length (mm) | Diameter (mm) | | | Single Strand | 180-300 | 8-12 (folded) | | | Quadruple Strand | 50-85 | 8-13 | | Indications for Use: | The Pre-Sutured Tendon is intended for use as a construct in anterior cruciate ligament and posterior cruciate ligament reconstruction. The Pre-Sutured Tendon is for single patient use only. | | | | Comparison of Technological Characteristics with the Predicate Device: | There are no technological differences between the subject and predicate device. However, there are minor dimensional differences between the subject device and the predicate devices, and gracilis tendon has been added as a source tendon for the subject device. These differences do not affect the intended use, performance, safety, design or function of the subject device for its intended use in anterior cruciate ligament and posterior cruciate ligament reconstruction. | | | | Performance Data: | Bench tests, which included ultimate load, cyclic displacement, and suture pull out confirmed that the Pre-Sutured Tendon with expanded ranges of length and diameter and the Gracilis source tendon meets the same requirements as the predicate device. Therefore, the predicate demonstrates substantial equivalence and meets the functional requirements set for the PST device. There is no change to the non-clinical testing data submitted in the original submission K230036 to demonstrate substantial equivalence including packaging validation, tissue sterilization and viral inactivation, shelf-life, and | | | {5} K253145 Page 2/2 | | biocompatibility. Bacterial endotoxin testing was also completed and results demonstrated that the subject device is substantially equivalent to the predicate. | | --- | --- | | Substantial Equivalence: | The subject device was demonstrated to be substantially equivalent to the predicate device cited above with respect to indications for use, aseptic processing, design, size, materials, function, storage, and performance. | | Conclusion: | The Pre-Sutured Tendon is substantially equivalent to the predicate device with respect to indications for use, tissue sterilization processes, aseptic packaging, design, function, materials, and performance. Product safety and performance are adequately supported by the substantial equivalence of information and test results. |
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%